Dr. Gregory Robertson’s research is focused on the field of Mycobacterium tuberculosis host-pathogen interactions with emphasis on the development of novel preclinical tools, use of TB mouse models for drug evaluation, and evaluation of drug activity and resistance in vitro and in vivo. He also leads preclinical animal studies as part of the Consortium for Applied Microbial Metrics including other investigators from the University of California San Francisco, Denver VA Medical Center, and CU Anschutz Medical Campus.
We are looking for talented researchers to join our team!
People
news and updates view all
Greg Robertson was named to the NIH PReclinical DesIgn and Clinical Translation of TB Regimens (PReDicTR) Consortium.
A collaborative study, including the CSU Mycobacteria Research Laboratories, provides an important new basis for comparing the effectiveness of different tuberculosis treatments and accelerating the development of shorter regimens.
The Consortium for Applied Microbial Metrics led by scientists at the University of Colorado Anschutz Medical Campus, Colorado State University and University of California San Francisco, combines insights from in vitro, animal and human studies to identify better tuberculosis treatments.
contact information
Office:
Microbiology room B308
Laboratory:
Microbiology room B331
(970) 491-3750
[email protected]